HC Wainwright reissued their buy rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a report released on Wednesday, Benzinga reports. HC Wainwright currently has a $21.00 price target on the stock.
Several other equities research analysts have also recently issued reports on ORIC. Cantor Fitzgerald reiterated an overweight rating on shares of ORIC Pharmaceuticals in a report on Monday, September 9th. Oppenheimer lowered their price target on ORIC Pharmaceuticals from $17.00 to $15.00 and set an outperform rating on the stock in a research note on Tuesday, August 13th. Wedbush reissued an outperform rating and issued a $20.00 price objective on shares of ORIC Pharmaceuticals in a research note on Tuesday, September 10th. Finally, Stifel Nicolaus started coverage on shares of ORIC Pharmaceuticals in a research note on Friday, September 6th. They set a buy rating and a $20.00 target price on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of Buy and a consensus price target of $18.00.
View Our Latest Research Report on ORIC
ORIC Pharmaceuticals Trading Up 0.8 %
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Research analysts predict that ORIC Pharmaceuticals will post -1.78 EPS for the current year.
Hedge Funds Weigh In On ORIC Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in ORIC. China Universal Asset Management Co. Ltd. increased its stake in shares of ORIC Pharmaceuticals by 104.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 12,922 shares of the company’s stock worth $178,000 after acquiring an additional 6,617 shares during the last quarter. ProShare Advisors LLC acquired a new stake in ORIC Pharmaceuticals during the first quarter worth about $161,000. Vanguard Group Inc. raised its stake in ORIC Pharmaceuticals by 27.9% during the first quarter. Vanguard Group Inc. now owns 2,882,055 shares of the company’s stock worth $39,628,000 after purchasing an additional 629,536 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in ORIC Pharmaceuticals by 140.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,566,736 shares of the company’s stock valued at $21,543,000 after purchasing an additional 915,175 shares during the last quarter. Finally, NEA Management Company LLC purchased a new stake in shares of ORIC Pharmaceuticals in the 1st quarter valued at approximately $20,625,000. Hedge funds and other institutional investors own 95.05% of the company’s stock.
About ORIC Pharmaceuticals
ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
Read More
- Five stocks we like better than ORIC Pharmaceuticals
- How to buy stock: A step-by-step guide for beginners
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What is a Special Dividend?
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for ORIC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORIC Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.